Alpa Laboratories Ltd Falls to 52-Week Low of Rs.67.83

Recent Price Movement and Market Context

On 20 Jan 2026, Alpa Laboratories Ltd’s stock price touched Rs.67.83, its lowest level in the past year. This decline comes after two consecutive days of losses, during which the stock has fallen by 5.72%. Despite this, the stock marginally outperformed its sector by 0.4% on the day. However, it remains substantially below its 52-week high of Rs.136.90, representing a drop of over 50% from that peak.

The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained bearish trend. This contrasts with the broader market, where the Sensex, despite a negative close at 82,916.92 (down 0.4%), remains 3.91% shy of its 52-week high of 86,159.02. The Sensex has experienced a three-week consecutive decline, losing 3.32% over that period, indicating some sector-wide pressures.

Financial Performance and Profitability Concerns

Alpa Laboratories Ltd’s financial metrics reveal challenges that have contributed to the stock’s decline. The company reported a Profit Before Tax (PBT) less other income of Rs. -2.95 crores in the September 2025 quarter, a steep fall of 619.8% compared to the previous four-quarter average. Similarly, the Profit After Tax (PAT) for the quarter was Rs.0.11 crores, down 98.3% from the prior average, indicating a near break-even position.

Return on Capital Employed (ROCE) for the half-year stood at 12.57%, the lowest recorded in recent periods, reflecting diminished efficiency in generating returns from capital invested. Additionally, the company’s operating profit has contracted at an annualised rate of -206.03% over the last five years, underscoring persistent difficulties in sustaining growth.

Valuation and Risk Profile

The stock’s Mojo Score currently stands at 17.0, with a Mojo Grade of Strong Sell, an upgrade from the previous Sell rating on 17 Nov 2025. This reflects a deteriorated outlook based on the company’s financial and market performance. The Market Cap Grade is rated at 4, indicating a relatively modest market capitalisation within its sector.

Alpa Laboratories Ltd’s valuation appears risky when compared to its historical averages. Over the past year, the stock has generated a negative return of 48.64%, while profits have declined by 10.4%. The company’s EBITDA has been negative, further emphasising the financial strain. This underperformance extends beyond the last year, with the stock lagging the BSE500 index over the past three years, one year, and three months.

Shareholding and Debt Position

The company maintains a low average Debt to Equity ratio of zero, indicating minimal leverage. Promoters remain the majority shareholders, maintaining control over the company’s strategic direction. This capital structure suggests limited financial risk from debt obligations, though it has not translated into improved profitability or share price performance.

Sector and Broader Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Alpa Laboratories Ltd’s performance has been notably weaker than peers. While the sector has seen mixed results amid market volatility, the company’s share price decline and financial metrics place it at a disadvantage relative to competitors. The Sensex’s recent three-week decline of 3.32% and its position below the 50-day moving average reflect some sector-wide pressures, but Alpa Laboratories Ltd’s 48.64% negative return over the past year far exceeds the broader market’s 7.59% gain.

This divergence highlights the company’s specific challenges in maintaining growth and profitability, despite operating in a sector that has generally shown resilience.

Summary of Key Metrics

To summarise, Alpa Laboratories Ltd’s stock has reached a 52-week low of Rs.67.83, down from a high of Rs.136.90 within the last year. The stock’s Mojo Grade has been downgraded to Strong Sell, reflecting deteriorated fundamentals. Financial results show a sharp decline in profitability, with PBT and PAT falling significantly in recent quarters. The company’s ROCE is at a low point, and negative EBITDA signals ongoing financial pressure. Despite a low debt burden and promoter control, the stock’s valuation and returns remain under strain compared to sector and market benchmarks.

These factors collectively explain the stock’s recent price weakness and its position at a new 52-week low.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →